J Nucl Med manuscript


Our newly developed monoclonal antibody 5D3 specifically targeting human prostate-specific antigen (PSMA) was radiolabeled with 111In-DOTA and used in a mouse model of prostate cancer as an imaging modality and a surrogate for therapy of malignant tissues expressing PSMA.  We plan on humanizing 5D3 mAb for future use in human medicine. Congrat to all co-authors for an excellent job!